Daewha's Paclitaxel formula successfully completed clinical tests.

Published: 2005-12-05 07:00:00

Updated: 2005-12-05 07:00:00

Daewha announced on Nov. 29 that the patent registration for the manufacturing process of a soluble and mucus absorbable formula of paclitaxel from its original insoluble substance had been completed.

The company said that the patent of this new DDS formula showed significant advantages in its...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK